Dr. Perl on the Outlook of FLT3 Inhibitors for AML

Alexander E. Perl, MD
Published: Thursday, Nov 02, 2017



Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

The first FLT3 inhibitor, midostaurin, is not potent enough against FLT3 and is more like a multikinase inhibitor. As a result, the newer FLT3 inhibitors are more potent and selective, explains Perl.

Perl says he is optimistic about patients with FLT3 mutations, as ongoing phase III trials have either completed or will soon complete accrual in relapsed or refractory patients with FLT3 mutations.
SELECTED
LANGUAGE


Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

The first FLT3 inhibitor, midostaurin, is not potent enough against FLT3 and is more like a multikinase inhibitor. As a result, the newer FLT3 inhibitors are more potent and selective, explains Perl.

Perl says he is optimistic about patients with FLT3 mutations, as ongoing phase III trials have either completed or will soon complete accrual in relapsed or refractory patients with FLT3 mutations.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x